Teetering Akorn hit with another FDA warning letter

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jun 25, 2019 at 7:32 PM.

  1. #1 cafead, Jun 25, 2019 at 7:32 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via For Akorn, when it rains, it monsoons. The sterile and generics maker, whose $4.3 billion buyout by Fresenius was swept away because of manufacturing failures, has received its second warning letter this year, even as it is in the process of renegotiating its loans with lenders.

    article source
     
    Quote

Reply to Thread